Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC Device Claims For COPD ‘Therapy’ Put Patients At Risk – UK Regulator

Executive Summary

ASA finds device marketer BioLife Solutions could not rely on a disclaimer and use of the word “therapy” instead of “treatment” to offset the message its Airnergy device treats a medical condition. ASA advices not to make COPD treatment claims unless a product is properly certified.

You may also be interested in...

UK Homeopathic Energy 'Balance' Claims Tilt Consumers Toward Trouble

UK regulator tells Natural Healing Solutions to discontinue online claims its products are “programmed” with resonance patterns to read energy levels and prevent disease. In a ruling published April 19, the agency noted the company acknowledged receipt of the complaint, but did not respond.

Industry Roundup: DXM Bill Moves, CHPA Biz Dev VP, Neurobrands Injunction

House subcommittee approves DXM Abuse bill; UK ire for US firm’s patch claims; Innophos VP hire; and more news in brief.

US FDA Cosmetics Director Lists Talc, Formaldehyde In Hair Smoothers Among Priorities

Linda Katz, director of the FDA’s Office of Cosmetics and Colors, touched on cosmetics modernization legislation in her 21 September presentation on agency priorities at the Independent Beauty Association’s virtual FDA Cosmetics Regulations Workshop.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts